- Home
- FOXX vs RNTX Comparison
FOXX vs RNTX Comparison
Compare FOXX & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOXX
- RNTX
- Stock Information
- Founded
- FOXX 2017
- RNTX 2001
- Country
- FOXX United States
- RNTX United States
- Employees
- FOXX N/A
- RNTX N/A
- Industry
- FOXX
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- FOXX
- RNTX Health Care
- Exchange
- FOXX Nasdaq
- RNTX Nasdaq
- Market Cap
- FOXX 37.7M
- RNTX 40.3M
- IPO Year
- FOXX N/A
- RNTX N/A
- Fundamental
- Price
- FOXX $6.50
- RNTX $1.46
- Analyst Decision
- FOXX
- RNTX
- Analyst Count
- FOXX 0
- RNTX 0
- Target Price
- FOXX N/A
- RNTX N/A
- AVG Volume (30 Days)
- FOXX 8.4K
- RNTX 40.5K
- Earning Date
- FOXX 08-15-2025
- RNTX 08-13-2025
- Dividend Yield
- FOXX N/A
- RNTX N/A
- EPS Growth
- FOXX N/A
- RNTX N/A
- EPS
- FOXX N/A
- RNTX N/A
- Revenue
- FOXX $53,866,257.00
- RNTX N/A
- Revenue This Year
- FOXX N/A
- RNTX N/A
- Revenue Next Year
- FOXX N/A
- RNTX N/A
- P/E Ratio
- FOXX N/A
- RNTX N/A
- Revenue Growth
- FOXX 3899.98
- RNTX N/A
- 52 Week Low
- FOXX $2.45
- RNTX $1.33
- 52 Week High
- FOXX $12.80
- RNTX $4.40
- Technical
- Relative Strength Index (RSI)
- FOXX N/A
- RNTX N/A
- Support Level
- FOXX N/A
- RNTX N/A
- Resistance Level
- FOXX N/A
- RNTX N/A
- Average True Range (ATR)
- FOXX 0.00
- RNTX 0.00
- MACD
- FOXX 0.00
- RNTX 0.00
- Stochastic Oscillator
- FOXX 0.00
- RNTX 0.00
About FOXX Foxx Development Holdings Inc. Common Stock
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.